Efficacy of Aliskiren in Japanese Chronic Kidney Disease Patients with Hypertension

REFERENCES

• Berl T. Review: Renal protection by inhibition of the renin–angiotensin–aldosterone system. J Renin Angiotensin Aldosterone Syst. 2009;10(1):1–8.
   Google Scholar
• Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–2446.
   PubMed Web of Science ®Google Scholar
• Schernthaner G. Dual inhibition with losartan and aliskiren: A promising therapeutic option for type 2 diabetic nephropathy? Nat Clin Pract Nephrol. 2008;4:656–657.
   Google Scholar
• Siamopoulos KC, Kalaitzidis RG. Inhibition of the renin–angiotensin system and chronic kidney disease. Int Urol Nephrol. 2008;40(4):1015–1025.
   PubMedGoogle Scholar
• Abassi Z, Winaver J, Feuerstein GZ. The biochemical pharmacology of renin inhibitors: Implications for translational medicine in hypertension, diabetic nephropathy and heart failure: Expectations and reality. Biochem Pharmacol. 2009;78(8):933–940.
   Google Scholar
• Parving H-H, Brenner BM, McMurray JJV, . Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplant. 2009;24:1663–1671.
   PubMed Web of Science ®Google Scholar
• Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res. 2006;29:997–1005.
   PubMed Web of Science ®Google Scholar
• Peixoto AJ, Orias M. Is there a role for direct renin inhibitors in chronic kidney disease? Curr Opin Nephrol Hypertens. 2009;18(5):397–403.
   Google Scholar
• Schmieder RE, Philipp T, Guerediaga J, . Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: A 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009;119:417–425.
   PubMed Web of Science ®Google Scholar
• Pool JL, Schmieder RE, Azizi M, . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11–20.
   PubMed Web of Science ®Google Scholar
• Wiggins KJ, Kelly DJ. Aliskiren: A novel renoprotective agent or simply an alternative to ACE inhibitors? Kidney Int. 2009;76(1):23–31.
   PubMed Web of Science ®Google Scholar
• Siragy HM. Rationale for combining a direct renin inhibitor with other renin–angiotensin system blockers. Focus on aliskiren and combinations. Cardiovasc Drugs Ther. 2011;25:87–97.
   Google Scholar
• Solomon SD, Appelbaum E, Manning WJ, . Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119:530–537.
   PubMed Web of Science ®Google Scholar
• Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res. 2011;34(3):308–313.
   PubMed Web of Science ®Google Scholar
• Moriyama T, Tsuruta Y, Kojima C, . Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. Int Urol Nephrol. 2011.
   Google Scholar
• Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant. 2011 ;26:2930–2934.
   Google Scholar
• Trimarchi H. Role of aliskiren in blood pressure control and renoprotection. Int J Nephrol Renovasc Dis. 2011;4:41–48.
   Google Scholar
• Matsuo S, Imai E, Horio M, . Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–992.
   PubMed Web of Science ®Google Scholar
• Alfie J, Aparicio LS, Waisman GD. Current strategies to achieve further cardiac and renal protection through enhanced renin–angiotensin–aldosterone system inhibition. Rev Recent Clin Trials. 2011;6:134–146.
   PubMedGoogle Scholar
• Chaudhary K, Nistala R, Whaley-Connell A. Is there a future for direct renin inhibitors? Expert Opin Investig Drugs. 2010;19(5):653–661.
   PubMed Web of Science ®Google Scholar
• Siragy HM. A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vasc Health Risk Manag. 2011;7:297–313.
   PubMedGoogle Scholar
• Ito S, Nakura N, Le Breton S, Keefe D. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res. 2009;33:62–66.
   Google Scholar
• Tang SCW, Lin M, Tam S, . Aliskiren combined with losartan in immunoglobulin A nephropathy: An open-labeled pilot study. Nephrol Dial Transplant. 2011;1–6.
   Google Scholar
• Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin–angiotensin–aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl. 2005;68(99):S57–S65.
   Google Scholar
• Weir MR. Effects of renin–angiotensin system inhibition on end-organ protection: Can we do better? Clin Ther. 2007;29(9):1803–1824.
   PubMed Web of Science ®Google Scholar
• Venzin RM, Cohen CD, Maggiorini M, Wuthrich RP. Aliskiren-associated acute renal failure with hyperkalemia. Clin Nephrol. 2009;71(3)326–328.
   PubMed Web of Science ®Google Scholar